title: Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience.
abstract: The HIV Resistance Response Database Initiative (RDI), which comprises a small research team in the United Kingdom and collaborating clinical centers in more than 15 countries, has used antiretroviral treatment and response data from thousands of patients around the world to develop computational models that are highly predictive of virologic response. The potential utility of such models as a tool for assisting treatment selection was assessed in two clinical pilot studies: a prospective study in Canada and Italy, which was terminated early because of the availability of new drugs not covered by the system, and a retrospective study in the United States. For these studies, a Web-based user interface was constructed to provide access to the models. Participating physicians entered baseline data for cases of treatment failure and then registered their treatment intention. They then received a report listing the five alternative regimens that the models predicted would be most effective plus their own selection, ranked in order of predicted virologic response. The physicians then entered their final treatment decision. Twenty-three physicians entered 114 cases (75 unique cases with 39 entered twice by different physicians). Overall, 33% of treatment decisions were changed following review of the report. The final treatment decisions and the best of the RDI alternatives were predicted to produce greater virologic responses and involve fewer drugs than the original selections. Most physicians found the system easy to use and understand. All but one indicated they would use the system if it were available, particularly for highly treatment-experienced cases with challenging resistance profiles. Despite limitations, the first clinical evaluation of this approach by physicians with substantial HIV-experience suggests that it has the potential to deliver clinical and economic benefits.
authors.affiliation: The HIV Resistance Response Database Initiative (RDI), London, United Kingdom.
authors.forename: Brendan A
authors.initials: BA
authors.lastname: Larder
authors.forename: Andrew
authors.initials: A
authors.lastname: Revell
authors.forename: Joann M
authors.initials: JM
authors.lastname: Mican
authors.forename: Brian K
authors.initials: BK
authors.lastname: Agan
authors.forename: Marianne
authors.initials: M
authors.lastname: Harris
authors.forename: Carlo
authors.initials: C
authors.lastname: Torti
authors.forename: Ilaria
authors.initials: I
authors.lastname: Izzo
authors.forename: Julia A
authors.initials: JA
authors.lastname: Metcalf
authors.forename: Migdalia
authors.initials: M
authors.lastname: Rivera-Goba
authors.forename: Vincent C
authors.initials: VC
authors.lastname: Marconi
authors.forename: Dechao
authors.initials: D
authors.lastname: Wang
authors.forename: Daniel
authors.initials: D
authors.lastname: Coe
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
authors.forename: Julio
authors.initials: J
authors.lastname: Montaner
authors.forename: H Clifford
authors.initials: HC
authors.lastname: Lane
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003198:Computer Simulation; D003657:Decision Making; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008962:Models, Theoretical; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents